4:15 PM
 | 
Mar 08, 2019
 |  BC Extra  |  Clinical News

Jounce seeking tumor-agnostic approach for ICOS agonist

Jounce said the ICOS hi CD4 T cells biomarker could allow the company to take a tumor-agnostic approach for its ICOS agonist vopratelimab (JTX-2011) to select patient populations more likely to respond to the therapy. Jounce Therapeutics Inc. (NASDAQ:JNCE) announced the news in its 4Q18 financial results Wednesday, then gained $1.06 (24%) to $5.45 on Thursday.

At the J.P. Morgan Healthcare Conference in January, President and CEO Richard Murray said that responses to vopratelimab were associated with...

Read the full 365 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >